Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Raikou

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Health Economics|May 4, 2004
Estimating medical care costs under conditions of censoringM Raikou, A McGuire
International Journal of Technology Assessment in Health Care|January 13, 2001
Where are the economic guidelines coming from?A McGuire, S Morris, M Raikou
Health Economics|May 3, 2000
Centre-specific or average unit costs in multi-centre studies? Some theory and simulationM Raikou, A Briggs, A Gray, et al.
BMJ (Clinical Research Ed.)|January 23, 1998
Use of statins. Glasgow has already produced strategy for treatmentJ McMurray, A McGuire, M Raikou, et al.
Diabetologia|April 25, 2001
Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51)P Clarke, A Gray, A Adler, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 27, 2001
An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54)A Gray, P Clarke, M Raikou, et al.
BMJ (Clinical Research Ed.)|May 20, 2000
Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study GroupA Gray, M Raikou, A McGuire, et al.
Diabetologia|February 1, 2007
Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)M Raikou, A McGuire, H M Colhoun, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Health Economics|May 4, 2004
Estimating medical care costs under conditions of censoringM Raikou, A McGuire
International Journal of Technology Assessment in Health Care|January 13, 2001
Where are the economic guidelines coming from?A McGuire, S Morris, M Raikou
Health Economics|May 3, 2000
Centre-specific or average unit costs in multi-centre studies? Some theory and simulationM Raikou, A Briggs, A Gray, et al.
BMJ (Clinical Research Ed.)|January 23, 1998
Use of statins. Glasgow has already produced strategy for treatmentJ McMurray, A McGuire, M Raikou, et al.
Diabetologia|April 25, 2001
Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51)P Clarke, A Gray, A Adler, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 27, 2001
An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54)A Gray, P Clarke, M Raikou, et al.
BMJ (Clinical Research Ed.)|May 20, 2000
Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study GroupA Gray, M Raikou, A McGuire, et al.
Diabetologia|February 1, 2007
Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)M Raikou, A McGuire, H M Colhoun, et al.
Pageof 1